Table 2. Animal models of SNHL induced by platinum antitumor drugs.
| Drug | Animal | Route | Dose | Schedule | Duration | Ototoxicity | Reference |
|---|---|---|---|---|---|---|---|
| Cis | C57BL/6 mouse | i.p. | 12 mg/kg | Single-dose | 1 day | OHCs were significantly reduced at 72 h after treatment in the apical, middle, and basal turns. IHCs remained intact. ABR thresholds increased 4 h and 72 h after treatment | (56) |
| Cis | Wistar rat | i.p. | 16 mg/kg | Single-dose | 1 day | OHCs and IHCs damaged. DPOAE values decreased | (57) |
| Cis | Guinea pig | i.p. | 12 mg/kg | Single-dose | 1 day | OHCs partially lost throughout the cochlea. ABR threshold shifted | (58,59) |
| Cis | Fischer 344/NHsd rat | i.p. | 12 mg/kg | Single-dose | 1 day | OHC loss increased from the apex to the base. ABR thresholds increased | (60) |
| Carb | Wistar rat | i.p. | 256 mg/kg | Single-dose | 1 day | ABR thresholds increased 4 days after treatment | (61) |
| Carb | Chinchilla | i.v. | 400 mg/m2 | Single-dose | 1 day | ABR and CAP thresholds increased | (62) |
| Carb | Chinchilla | i.v. | 200 mg/m2 | Single-dose | 1 day | Loss of IHCs. ABR thresholds increased | (63) |
| Carb | Chinchilla | i.p. | 75 mg/kg | Single-dose | 1 day | Loss of 40% of IHCs. The amplitude of SP and CAP declined | (64) |
SNHL, sensorineural hearing loss; cis, cisplatin; carb, carboplatin; furo, furosemide i.v., intraveneous; i.p., intraperitoneal; OHCs, outer hair cells; IHCs, inner hair cells; ABR, auditory brainstem response; DPOAE, distortion product otoacoustic emission; CAP, compound action potential; SP, summating potential.